Mounjaro Now Available: NZ Pharmacy Stock Arrives

After months of anticipation following Medsafe approval in December 2025, Mounjaro is arriving in New Zealand pharmacies. Stock is expected within days, with major pharmacy chains now accepting prescriptions.

‍

What We Know

Chemist Warehouse has confirmed pricing and is preparing to dispense Mounjaro prescriptions, with stock expected imminently. This marks the first time New Zealanders can access tirzepatide through local pharmacies rather than overseas suppliers.

Mounjaro will be available as the KwikPen, a multi-use prefilled pen that delivers four weekly doses. Each pen represents 4 weeks of treatment.

‍

Pricing Overview

Monthly costs range from $429.99 to $874.99 depending on your prescribed dose:

• 2.5 mg (starting dose): $429.99
• 5 mg: $499.99
• 7.5 mg: $689.99
• 10 mg: $689.99
• 12.5 mg: $874.99
• 15 mg (maximum): $874.99

Free shipping is available from Chemist Warehouse.

‍

Who Can Use Mounjaro?

Mounjaro is approved for adults in two categories:

Weight management: Adults with a BMI of 30 or above (obesity), or BMI of 27 or above (overweight) with at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes.

Type 2 diabetes: Adults with insufficiently controlled blood sugar, used alongside diet and exercise.

For more, see Who Can Take Mounjaro? Eligibility Requirements in NZ

‍

How Mounjaro Works

Mounjaro is the first dual GIP and GLP-1 receptor agonist. It targets two hormone pathways involved in appetite regulation and blood sugar control, which may explain why clinical trials show greater weight loss compared to GLP-1-only medications like Wegovy and Ozempic.

In the SURMOUNT-1 trial, participants without diabetes lost an average of 22.5% of their body weight on the highest dose over 72 weeks.

‍

What to Do Next

If you're interested in Mounjaro, you'll need a prescription from a registered healthcare professional. This involves a consultation to assess your eligibility based on BMI, health history, and current medications.

For those already using Wegovy or other GLP-1 medications, switching to Mounjaro is possible once stock is available. Discuss timing and transition with your prescriber.

Mounjaro is not funded by PHARMAC. All costs are out-of-pocket.

At Well Revolution, we offer a free initial consultation to determine if Mounjaro is safe and appropriate for you.